Breaking News

ProBioGen, Merus Sign GlymaxX License Agreement

By Kristin Brooks | March 4, 2014

Will use the technology to enhance the ADCC activity lead product

ProBioGen AG and Merus B.V. have signed a non-exclusive commercial option and license agreement granting Merus access to ProBioGen’s GlymaxX fucose-engineering technology to enhance the ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity for its lead product, a bispecific anti-cancer antibody. The license covers clinical development and production. Financial details were not disclosed.
 
"We are very satisfied to see our GlymaxX technology being applied to Merus’ promising bispecific cancer antibody candidate. This underlines the superiority of our ADCC enhancement technology and its ability to deliver smart and flexible solutions for optimized biopharmaceutical products," said Volker Sandig, chief scientific officer of ProBioGen AG. “We are convinced that our GlymaxX technology will make a significant contribution to develop powerful new antibodies against any diseases in which enhanced ADCC activity translates into therapeutic benefit.”
 
“The GlymaxX technology substantially improves the ADCC activity of one of our lead bispecific antibodies for the treatment of solid tumors so that it further enhances the tumor cell killing capacity of an already very potent molecule,” said Mark Throsby, chief scientific officer of Merus B.V.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.